The focus during the financial year ended 30 June 2022 has been to progress the growth and expansion strategy to diversify towards a sustainable pharmaceutical group.
Expansion of Melanocortin Drug Portfolio
Introduced ACTH formulation, NEURACTHEL® for acute neurological, endocrinological and degenerative disorders
Distribution of SCENESSE®
Continued growth in patient access in the EEA, the USA and Israel
Reimbursement of SCENESSE® agreed with State and Private insurers in Germany
Healthcare Solutions Progressed
Ongoing development of a dermatocosmetic product range
Digital marketing campaign commenced ahead of first product launch
Expanded Clinical Programs Advanced
First stroke study commenced, completed and results announced
Three studies commenced in DNA Repair Program
Design of new vitiligo study agreed; SCENESSE® to be evaluated as monotherapy
Strong Financial Performance
Growth reflected in record operating profit, half year to 31 December 2021 and full year to 30 June 2022
Sixth consecutive annual profit delivered
Highest cash receipts for a September, December, March, and June quarter achieved throughout the year
Fifth consecutive annual dividend declared
Cash balances rose to over A$121 million to enable self-financing of key initiatives